N-Acetylcysteine derivative inhibits procoagulant activity of human islet cells.

C. Beuneu, O. Vosters, Z. Ling, D. Pipeleers, O. Pradier, M. Goldman, V. Verhasselt

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

AIMS/HYPOTHESIS: The early loss of beta cells after islet cell transplantation has been attributed in part to blood coagulation at the implant site. Tissue factor expressed by beta cells and contaminating duct cells is considered to activate this process. Here, we investigated the ability of N-acetyl-L-cysteine to suppress the in vitro procoagulant activity of duct cells and human islet cell preparations. MATERIALS AND METHODS: The effects of Nacystelyn, a salt derivative of N-acetyl-L-cysteine, were first assessed on procoagulant activity induced in human plasma by recombinant tissue factor, human primary duct cells or human islet cell preparations. The influence of Nacystelyn on clot formation, platelet counts and D-dimers were measured in a whole blood tubing loop model. Human beta cell viability and insulin synthesis after Nacystelyn treatment were assessed to exclude cytotoxicity of Nacystelyn. RESULTS: Nacystelyn efficiently inhibited the procoagulant activity of human recombinant tissue factor, primary duct cells and human islet cell preparations at clinically relevant concentrations without cellular toxicity. CONCLUSIONS/INTERPRETATION: Nacystelyn is a pharmaceutical candidate to reduce early beta cell loss related to tissue factor-dependent coagulation after islet transplantation.

Original languageEnglish
Pages (from-to)343-347
Number of pages5
JournalDiabetologia
Volume50
Issue number2
DOIs
Publication statusPublished - 1 Feb 2007
Externally publishedYes

Fingerprint

Acetylcysteine
Islets of Langerhans
Human Activities
Thromboplastin
Islets of Langerhans Transplantation
Cell Transplantation
Blood Coagulation
Platelet Count
N-acetylcysteine lysinate
Cell Survival
Salts
Insulin
Pharmaceutical Preparations

Cite this

Beuneu, C., Vosters, O., Ling, Z., Pipeleers, D., Pradier, O., Goldman, M., & Verhasselt, V. (2007). N-Acetylcysteine derivative inhibits procoagulant activity of human islet cells. Diabetologia, 50(2), 343-347. https://doi.org/10.1007/s00125-006-0529-4
Beuneu, C. ; Vosters, O. ; Ling, Z. ; Pipeleers, D. ; Pradier, O. ; Goldman, M. ; Verhasselt, V. / N-Acetylcysteine derivative inhibits procoagulant activity of human islet cells. In: Diabetologia. 2007 ; Vol. 50, No. 2. pp. 343-347.
@article{799f582eae8f4d219d35b092c7bcc747,
title = "N-Acetylcysteine derivative inhibits procoagulant activity of human islet cells.",
abstract = "AIMS/HYPOTHESIS: The early loss of beta cells after islet cell transplantation has been attributed in part to blood coagulation at the implant site. Tissue factor expressed by beta cells and contaminating duct cells is considered to activate this process. Here, we investigated the ability of N-acetyl-L-cysteine to suppress the in vitro procoagulant activity of duct cells and human islet cell preparations. MATERIALS AND METHODS: The effects of Nacystelyn, a salt derivative of N-acetyl-L-cysteine, were first assessed on procoagulant activity induced in human plasma by recombinant tissue factor, human primary duct cells or human islet cell preparations. The influence of Nacystelyn on clot formation, platelet counts and D-dimers were measured in a whole blood tubing loop model. Human beta cell viability and insulin synthesis after Nacystelyn treatment were assessed to exclude cytotoxicity of Nacystelyn. RESULTS: Nacystelyn efficiently inhibited the procoagulant activity of human recombinant tissue factor, primary duct cells and human islet cell preparations at clinically relevant concentrations without cellular toxicity. CONCLUSIONS/INTERPRETATION: Nacystelyn is a pharmaceutical candidate to reduce early beta cell loss related to tissue factor-dependent coagulation after islet transplantation.",
author = "C. Beuneu and O. Vosters and Z. Ling and D. Pipeleers and O. Pradier and M. Goldman and V. Verhasselt",
year = "2007",
month = "2",
day = "1",
doi = "10.1007/s00125-006-0529-4",
language = "English",
volume = "50",
pages = "343--347",
journal = "Diabetolgia",
issn = "0012-186X",
publisher = "Springer",
number = "2",

}

Beuneu, C, Vosters, O, Ling, Z, Pipeleers, D, Pradier, O, Goldman, M & Verhasselt, V 2007, 'N-Acetylcysteine derivative inhibits procoagulant activity of human islet cells.' Diabetologia, vol. 50, no. 2, pp. 343-347. https://doi.org/10.1007/s00125-006-0529-4

N-Acetylcysteine derivative inhibits procoagulant activity of human islet cells. / Beuneu, C.; Vosters, O.; Ling, Z.; Pipeleers, D.; Pradier, O.; Goldman, M.; Verhasselt, V.

In: Diabetologia, Vol. 50, No. 2, 01.02.2007, p. 343-347.

Research output: Contribution to journalArticle

TY - JOUR

T1 - N-Acetylcysteine derivative inhibits procoagulant activity of human islet cells.

AU - Beuneu, C.

AU - Vosters, O.

AU - Ling, Z.

AU - Pipeleers, D.

AU - Pradier, O.

AU - Goldman, M.

AU - Verhasselt, V.

PY - 2007/2/1

Y1 - 2007/2/1

N2 - AIMS/HYPOTHESIS: The early loss of beta cells after islet cell transplantation has been attributed in part to blood coagulation at the implant site. Tissue factor expressed by beta cells and contaminating duct cells is considered to activate this process. Here, we investigated the ability of N-acetyl-L-cysteine to suppress the in vitro procoagulant activity of duct cells and human islet cell preparations. MATERIALS AND METHODS: The effects of Nacystelyn, a salt derivative of N-acetyl-L-cysteine, were first assessed on procoagulant activity induced in human plasma by recombinant tissue factor, human primary duct cells or human islet cell preparations. The influence of Nacystelyn on clot formation, platelet counts and D-dimers were measured in a whole blood tubing loop model. Human beta cell viability and insulin synthesis after Nacystelyn treatment were assessed to exclude cytotoxicity of Nacystelyn. RESULTS: Nacystelyn efficiently inhibited the procoagulant activity of human recombinant tissue factor, primary duct cells and human islet cell preparations at clinically relevant concentrations without cellular toxicity. CONCLUSIONS/INTERPRETATION: Nacystelyn is a pharmaceutical candidate to reduce early beta cell loss related to tissue factor-dependent coagulation after islet transplantation.

AB - AIMS/HYPOTHESIS: The early loss of beta cells after islet cell transplantation has been attributed in part to blood coagulation at the implant site. Tissue factor expressed by beta cells and contaminating duct cells is considered to activate this process. Here, we investigated the ability of N-acetyl-L-cysteine to suppress the in vitro procoagulant activity of duct cells and human islet cell preparations. MATERIALS AND METHODS: The effects of Nacystelyn, a salt derivative of N-acetyl-L-cysteine, were first assessed on procoagulant activity induced in human plasma by recombinant tissue factor, human primary duct cells or human islet cell preparations. The influence of Nacystelyn on clot formation, platelet counts and D-dimers were measured in a whole blood tubing loop model. Human beta cell viability and insulin synthesis after Nacystelyn treatment were assessed to exclude cytotoxicity of Nacystelyn. RESULTS: Nacystelyn efficiently inhibited the procoagulant activity of human recombinant tissue factor, primary duct cells and human islet cell preparations at clinically relevant concentrations without cellular toxicity. CONCLUSIONS/INTERPRETATION: Nacystelyn is a pharmaceutical candidate to reduce early beta cell loss related to tissue factor-dependent coagulation after islet transplantation.

UR - http://www.scopus.com/inward/record.url?scp=34247216064&partnerID=8YFLogxK

U2 - 10.1007/s00125-006-0529-4

DO - 10.1007/s00125-006-0529-4

M3 - Article

VL - 50

SP - 343

EP - 347

JO - Diabetolgia

JF - Diabetolgia

SN - 0012-186X

IS - 2

ER -

Beuneu C, Vosters O, Ling Z, Pipeleers D, Pradier O, Goldman M et al. N-Acetylcysteine derivative inhibits procoagulant activity of human islet cells. Diabetologia. 2007 Feb 1;50(2):343-347. https://doi.org/10.1007/s00125-006-0529-4